Vor Biopharma Inc. (NYSE:VOR) shares fell 2.8% during trading on Friday . The stock traded as low as $21.65 and last traded at $21.65. 264 shares traded hands during trading, a decline of 100% from the average session volume of 215,400 shares. The stock had previously closed at $22.27.
A number of equities research analysts recently weighed in on VOR shares. Zacks Investment Research upgraded Vor Biopharma from a “sell” rating to a “hold” rating in a research report on Thursday, May 13th. The Goldman Sachs Group began coverage on shares of Vor Biopharma in a report on Tuesday, March 2nd. They set a “sell” rating and a $19.00 price target for the company. B. Riley reissued a “buy” rating and issued a $60.00 price objective on shares of Vor Biopharma in a research note on Friday, May 7th. Stifel Nicolaus began coverage on Vor Biopharma in a report on Tuesday, March 2nd. They issued a “buy” rating and a $58.00 target price on the stock. Finally, Evercore ISI began coverage on shares of Vor Biopharma in a research report on Tuesday, March 2nd. They issued an “outperform” rating and a $48.00 price target for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $48.20.
The business has a fifty day moving average of $25.72. The company has a market capitalization of $802.05 million and a PE ratio of -0.10.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Citigroup Inc. purchased a new stake in shares of Vor Biopharma in the first quarter valued at about $33,000. Royal Bank of Canada bought a new stake in Vor Biopharma in the 1st quarter worth about $46,000. Strs Ohio bought a new stake in Vor Biopharma in the 1st quarter worth about $116,000. Old Well Partners LLC purchased a new stake in Vor Biopharma in the 1st quarter valued at about $202,000. Finally, Pinz Capital Management LP bought a new position in shares of Vor Biopharma during the 1st quarter worth approximately $210,000. 82.70% of the stock is currently owned by hedge funds and other institutional investors.
About Vor Biopharma (NYSE:VOR)
Vor Biopharma, Inc, early-stage cell therapy company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in preclinical development to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML cancer cells.
Further Reading: When is a capital gain realized?
Receive News & Ratings for Vor Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vor Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.